Facebook-f Twitter Linkedin Youtube
SUBSCRIBE
Facebook-f Twitter Linkedin Youtube

Hematology / Oncology CE Activities

Hematology / oncology blog

View Details

Targeting BCMA: A New Path in Relapsed/Refractory Multiple Myeloma

In triple- and quad-refractory myeloma, median survival was only about 9 months, and less than 6 months in penta-refractory disease.
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Navigating Immunotherapy in Advanced NSCLC: What Every Oncologist Should Know

The advent of immunotherapy has significantly extended survival and revolutionized care in advanced non-small cell lung cancer (NSCLC).
  • Hematology / Oncology
  • Blog
DOWNLOAD
View Details

Is Immunotherapy Right for Your Patient with Nonmelanoma Skin Cancer?

The primary goal of treatment in nonmelanoma skin cancer (NMSC) is tumor elimination with maximal preservation of function and cosmesis.
  • Hematology / Oncology
  • Blog
DOWNLOAD

RMEI Presentations

RMEI DECISION SUPPORT AIDS

View Details

Intravitreal Anti-VEGF & Bispecific Therapies for DME & nAMD

In late 2022, the ocular implant, insertion tool assembly, (including the drug vial & initial fill needle) for ranibizumab PDS were voluntarily recalled due to septum dislodgement and paused implantations including ongoing global clinical trials; this did not include the refill vial and needle.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Cervical Cancer: What You Need to Know About Screening, Symptoms, and Treatments

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients. An estimated 13,960 women are diagnosed with invasive cervical cancer every year.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Seeing Nonmelanoma Skin Cancers Through A New Lens: The Role and Place of Immunotherapy

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD
View Details

Relapsed or Refractory Chronic-Phase: CHRONIC MYELOID LEUKEMIA (CML)

This Decision Support Aid serves as a quick reference to help clinicians to apply information to their daily practice and care of patients.
  • Hematology / Oncology
  • Decision Support Aid
DOWNLOAD

LATEST HEMATOLOGY / ONCOLOGY ARTICLES

RSS Latest Hematology / Oncology Articles
  • The Last Dose May 8, 2025
    When a dying patient’s parents refuse to give up hope, her physician opts to hope with them, going to unusual lengths to provide a last treatment he knows will be futile.
    David N. Korones
  • Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma May 8, 2025
    Among patients with smoldering multiple myeloma at high risk for progression, progression-free survival at 5 years was 63.1% with daratumumab monotherapy, as compared with 40.8% with active monitoring.
    Meletios A. Dimopoulos, Peter M. Voorhees, Fredrik Schjesvold, Yael C. Cohen, Vania Hungria, Irwindeep Sandhu, Jindriska Lindsay, Ross I. Baker, Kenshi Suzuki, Hiroshi Kosugi, Mark-David Levin, Meral Beksac, Keith Stockerl-Goldstein, Albert Oriol, Gabor Mikala, Gonzalo Garate, Koen Theunissen, Ivan Spicka, Anne K. Mylin, Sara Bringhen, Katarina Uttervall, Bartosz Pula, Eva Medvedova, Andrew J. Cowan, Philippe Moreau, Maria-Victoria Mateos, Hartmut Goldschmidt, Tahamtan Ahmadi, Linlin Sha, Annelore Cortoos, Eva G. Katz, Els Rousseau, Liang Li, Robyn M. Dennis, Robin Carson, S. Vincent Rajkumar, the AQUILA Investigators*
  • Targeting the Tumor and the Immune System in Smoldering Multiple Myeloma May 8, 2025
    Multiple myeloma is preceded by an asymptomatic expansion of clonal plasma cells that is detected clinically and described as smoldering multiple myeloma. Studies have identified a fraction of cases of smoldering multiple myeloma that are characterized by a high risk of early progression to multiple myeloma. Progression to multiple myeloma...
    Francesco Maura, P. Leif Bergsagel

RMEI LIGHTNING TALKS

View Details

4 Years, 16 Live & Online Activities, 6000+ Clinicians: What we've learned so far

RMEI has released pairings of live and online programs approximately twice per year since 2016 grouped into “phases” which share clinical areas of focus and are based on findings from the previous phase of education. In total, 16 activities have launched to date with 4 activities currently live. The purpose of this analysis is to better understand the impact of multi-year iterative education on a clinical audience. Presented at: Society for Academic CME (SACME), virtual, February 2021; Accreditation Council for Continuing Medical Education (ACCME), virtual, April 2021.
  • Allergy & Immunology
  • 2021
View Details

Effectiveness of 5-year IBD Provider Online Educational Intervention Program

There is considerable practice variability among providers caring for inflammatory bowel disease (IBD) patients. Limited data exists on the effectiveness of educational interventions targeting IBD providers to address these gaps. We report outcomes for a 5-year provider education training program which culminated in an enduring online education resource and clinical decision support tool.
  • Gastroenterology
  • 2021

Previously Published CE Activities

Copyright © 2025. RMEI Medical Education, LLC. All rights reserved​